KDR and plasma cell myeloma: By engaging VLA-4 and VEGFR2 on the myeloma cells and tumor suppressor cells in the tumor microenvironment, the shed syndecan is likely to promote VLA-4-mediated extravasation of myeloma cells in and out of the bone marrow and to extramedullary organs.